Galectin Therapeutics Inc. (GALT) News
Filter GALT News Items
GALT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GALT News Highlights
- For GALT, its 30 day story count is now at 4.
- Over the past 7 days, the trend for GALT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- PAR are the most mentioned tickers in articles about GALT.
Latest GALT News From Around the Web
Below are the latest news stories about GALECTIN THERAPEUTICS INC that investors may wish to consider to help them evaluate GALT as an investment opportunity.
Galectin Therapeutics Inc. (NASDAQ:GALT) surges 16%; individual investors who own 59% shares profited along with insidersKey Insights Significant control over Galectin Therapeutics by individual investors implies that the general public has... |
Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023NORCROSS, Ga., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held on September 11-13, 2022. The Wainwright Conference – which takes place at the Lotte New York Palace Hotel in New York City, New York – brings together thought leaders and practitioners from numerous fields to par |
Galectin Therapeutics Inc. (GALT)'s Technical Outlook is Bright After Key Golden CrossWhen a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react? |
Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023NORCROSS, Ga., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will participate in the 9th Edition of the Paris NASH meeting, where a select group of international experts gather each year at the prestigious Institut Pasteur in Paris to discuss the latest scientific and clinical research developments in non-alcoholic steatohepatitis (NASH) and its complications, includin |
What Makes Galectin Therapeutics Inc. (GALT) a New Buy StockGalectin Therapeutics Inc. (GALT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business UpdateNORCROSS, Ga., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2023. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Joel Lewis, Chief Executive Officer and President of G |
7 Short-Interest Stocks to Target for Explosive GainsFor contrarian investors that can stand the heat, short-interest stocks to buy can offer significant rewards in a short time period. |
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business UpdateNORCROSS, Ga., May 15, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2023. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Joel Lewis, Chief Executive Officer and President of G |
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023NORCROSS, Ga., April 27, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright BioConnect Investment Conference on Tuesday, May 2, 2023. Mr. Joel Lewis, Chief Executive Officer and President, and Dr. Pol F. Boudes, Chief Medical Officer, will participate in a fireside chat discussing the Company’s innovative NAVIGATE trial in NASH cirrhosis w |
Galectin Therapeutics’ Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver DiseasesNORCROSS, Ga., April 18, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, attended the 2023 Emerging Topic Conference on NASH Cirrhosis: From Mechanisms to Management, sponsored by the American Association for the Study of Liver Diseases (AASLD). The Conference took place in Los Angeles, March 25-26, 2023. The AASLD has created a new forum to share knowledge around NASH cirrhosis and explore current and futu |